Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Sunesis Pharmaceuticals
company
About
Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $43.50M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$43.50M
Sunesis Pharmaceuticals has raised a total of
$43.50M
in funding over 2 rounds. Their latest funding was raised on
Apr 7, 2009 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 7, 2009 | Post-IPO Equity | $43.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Sunesis Pharmaceuticals is funded by 1 investors.
Caxton Advantage Life Sciences Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Caxton Advantage Life Sciences Fund
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
